Beam Therapeutics’ $1.2B Cash Runway Fuels 2026 BLA for Sickle Cell Drug
BEAM•Beam Therapeutics holds $1.2 billion in cash, providing a funding runway through mid-2029 to advance pivotal base-editing programs. Its Risto-cel sickle cell therapy targets a BLA filing by year-end 2026 while BEAM-302 seeks accelerated approval for alpha-1 antitrypsin deficiency.
1. Cash Position and Runway
Beam Therapeutics reported a $1.2 billion cash and investment balance, extending its operational runway into mid-2029 to support development of its base-editing pipeline without immediate financing needs.
2. Risto-cel Sickle Cell Program
The company’s lead sickle cell candidate, Risto-cel, is designed to improve process efficiency and efficacy and is on track for a biologics license application submission by year-end 2026.
3. BEAM-302 AATD Program
BEAM-302, targeting alpha-1 antitrypsin deficiency, is advancing through pivotal studies with a strategy focused on securing accelerated regulatory approval based on early efficacy and safety data.
4. Investor Presentation Scheduled
CEO John Evans will present at the RBC Capital Markets Global Healthcare Conference on May 20 at 10:30 a.m. ET, with a live webcast and a 60-day archive available on the company website.
